Search Results

Summary The complete 145-2C11 antibody is commonly used to stimulate T cells in vitro however, when used in vivo activation of resting T cells results in cytokine release and toxicity caused by Ab-mediated cross-linking of T cells and Fcγ receptor-bearing cells. To avoid these complications non-Fc receptor binding F(ab’)2 fragments of the 145-2C11 antibody are commonly used. This non-FcR-binding anti-CD3 induces apoptosis of Ag-activated T cells in vivo  by allowing durable expression of the TCR and sustained signaling. Foxp3+ Tregs have been shown to be resistant to CD3 antibody-mediated depletion.

Summary This antibody reacts to both kappa and lambda light chains of human immunoglobulins. The antibody does not react to monkey (Cyno or Rhesus) IgG, mouse IgG, rat IgG, or goat IgG.

CD2 antibody [N1C1] Cat No. GTX101874

1 References

IP/MS

Summary IP/MS validation is based on published data (PMID: 30377379).

Summary This antibody recognizes the CD3 antigen of the TCR/CD3 complex on mature human T cells. This antibody, also known as Orthoclone OKT3 or Muromonab-CD3, has been extensively used as a drug for therapy of acute, glucocorticoid resistant rejection of allogenic renal, heart and liver transplants. It has also been investigated for use in treating T-cell acute lymphoblastic leukemia.